← All candidates
37 insider filings on record.
37 filings on record.
TNGXTango Therapeutics, Inc.
NasdaqGM · Healthcare · $4.05B
$24.54
-2.65% · Sep 15
37 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 15 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$4.05B
Float
120.3M
71% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
75.3
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
32 more transactions on Pro →Context
Wall St
$43.82 avg target
+78.6% vs today · 11 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.32 act−$0.01
Q4 '25−$0.29 act+$0.04
Q3 '25$0.13 act+$0.20
Q2 '25−$0.35 act−$0.01
Coverage
Tango Therapeutics Rides a New Precision Oncology Trend in 2026Zacks · 07-02Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?Zacks · 07-02TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 CatalystsZacks · 07-02Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One YearSimply Wall St. · 06-10
The file stays open
37 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice